Adaptive Biotechnologies Corporation (ADPT) vs BillionToOne, Inc. (BLLN)
Adaptive Biotechnologies Corporation and BillionToOne, Inc. are both Diagnostics & Research companies. BillionToOne, Inc. is the larger, with a market value of $5.9B against $4.7B — 1.3× the size. Adaptive Biotechnologies Corporation has negative trailing earnings, so its P/E is not meaningful; BillionToOne, Inc. trades at 119×. BillionToOne, Inc. has the higher net margin (8.35% vs −20.7%) and the higher return on invested capital (34.1% vs −16.6%). Across the 16 metrics below, BillionToOne, Inc. leads on 15 and Adaptive Biotechnologies Corporation on 1.
Valuation
Profitability
| Metric | ADPT | BLLN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 75.57% | 71.27% | 50.89% |
| Operating margin | (12.16%) | 10.90% | (8.57%) |
| Net margin | (20.73%) | 8.35% | (6.37%) |
| Free cash flow margin | (7.80%) | 8.35% | 0.00% |
| Return on equity | (38.68%) | 23.27% | (2.92%) |
| Return on assets | (11.23%) | 9.09% | (6.71%) |
| Return on invested capital | (16.57%) | 34.10% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack